Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Targeting endothelial junctional adhesion molecule-A/ EPAC/ Rap-1 axis as a novel strategy to increase stem cell engraftment in dystrophic muscles

  • Giannotta, Monica
  • Benedetti, Sara
  • Tedesco, Francesco Saverio
  • Corada, Monica
  • Trani, Marianna
  • D'Antuono, Rocco
  • Millet, Queensta
  • Orsenigo, Fabrizio
  • Galvez, Beatriz G.
  • Cossu, Giulio
  • Dejana, Elisabetta
Muscular dystrophies are severe genetic diseases for which no efficacious therapies exist. Experimental clinical treatments include intra-arterial administration of vessel-associated stem cells, called mesoangioblasts (MABs). However, one of the limitations of this approach is the relatively low number of cells that engraft the diseased tissue, due, at least in part, to the sub-optimal efficiency of extravasation, whose mechanisms for MAB are unknown. Leukocytes emigrate into the inflamed tissues by crossing endothelial cell-to-cell junctions and junctional proteins direct and control leukocyte diapedesis. Here, we identify the endothelial junctional protein JAM-A as a key regulator of MAB extravasation. We show that JAM-A gene inactivation and JAM-A blocking antibodies strongly enhance MAB engraftment in dystrophic muscle. In the absence of JAM-A, the exchange factors EPAC-1 and 2 are down-regulated, which prevents the activation of the small GTPase Rap-1. As a consequence, junction tightening is reduced, allowing MAB diapedesis. Notably, pharmacological inhibition of Rap-1 increases MAB engraftment in dystrophic muscle, which results into a significant improvement of muscle function offering a novel strategy for stem cell-based therapies.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Integrated 3D-Printed Hollow Microneedle Array and Lateral Flow Immunoassay for Point-of-Care Wound Healing Monitoring

  • Sena-Torralba, Amadeo
  • Parrilla, Marc
  • Hernanz-Grimalt, Ana
  • Steijlen, Annemarijn
  • Ortíz-Zapater, Elena
  • Cabaleiro, Cristina
  • López-Riquelme, María Natividad
  • Cerveró-Ferragut, Salvador
  • De Wael, Karolien
  • Maquieira, Angel|||0000-0003-4641-4957
  • Morais, Sergi|||0000-0002-3722-2358
[EN] Chronic wound management requires continuous monitoring to assess healing and guide treatment. We developed a hollow microneedle array patch integrated with a lateral flow immunoassay strip to address the need for convenient, home-based diagnostics. This device extracts wound exudate directly from the wound matrix, overcoming the limitations of conventional swab sampling, which relies on surface exudate collection. The patch provides a minimally invasive, rapid solution to assess the wound healing phase. The immunoassay delivers a colorimetric signal visible to the naked eye, facilitating straightforward interpretation by clinicians within 10 min. In a clinical study involving 90 patients, matrix metalloproteinase 8 (MMP-8) was identified as a critical biomarker, achieving 80.3% sensitivity in detecting the proliferative phase. A specific lateral flow immunoassay for MMP-8 was developed with a detection limit of 0.7 ng/mL, lower than the threshold level for the proliferative healing phase (164.7 ng/mL). The hollow microneedle array patch was 3D-printed for cost-efficiency (less than 0.10 per patch) with a height of 865 +/- 6 mu m, allowing for a painless, easy sampling. Mechanical tests confirmed the durability of the patch, while cytotoxicity assays demonstrated its biocompatibility. Prevalidation using an ex vivo skin model showed the patch could extract 61 +/- 6 mu L of exudate, with a 122% recovery rate for MMP-8 detection, highlighting its efficiency in biomarker extraction. This approach represents a significant advance in decentralized wound care, offering a low-cost, user-friendly tool for at-home monitoring of chronic wounds, potentially improving early intervention and reducing hospital visits., A.S.-T. acknowledges Generalitat Valenciana and the European Social Fund for the CIAPOS fellowship (CIAPOS/2022/7) and the Incoming Mobility Stay fellowship of FWO in Flanders, Belgium (V510323N). M.P. acknowledges the support of the Fund for Scientific Research (FWO) in Flanders (K217022N and 1265223N), Belgium. A.H.-G. acknowledges the fellowship Programa Investigo 2022 funded by the European Union - NextGenerationEU. A.S. recognizes support through a Rubicon fellowship from the Dutch Research Council (019.223EN.003). The research was financed by the UPP-DIAGNOSTIC 202-AP-13 grant from UniSalut Polisabio. The authors acknowledge BOF-UAntwerp, FWO infrastructure funding.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Combined treatment with recombinant tissue plasminogen activator and dexamethasone phosphate-containing liposomes improves neurological outcome and restricts lesion progression after embolic stroke in rats

  • Salas-Perdomo, Angélica
  • Planas, Anna M.
  • Dijkhuizen, Rick M.
Variable efficacies have been reported for glucocorticoid drugs as anti-inflammatory treatment after stroke. We applied an alternative drug delivery strategy, by injection of dexamethasone phosphate-containing liposomes in combination with recombinant tissue plasminogen activator (rtPA), in an experimental stroke model, and tested the hypothesis that this approach improves behavioral recovery and reduces lesion growth. Rats were subjected to right middle cerebral artery occlusion with a blood clot. After 2 h, animals were intravenously injected with rtPA plus empty long-circulating liposomes (LCL), free dexamethasone phosphate (DXP), or DXP-containing LCL (LCL-DXP). Neurological status was evaluated with different behavioral tests up to 7 days after stroke. Lesion development was assessed by magnetic resonance imaging of tissue and perfusion parameters from 0-2 h until 7 days after stroke. Expression of brain inflammatory markers was measured with RT-PCR at post-stroke day 7. Treatment with rtPA plus LCL-DXP resulted in significantly improved behavioral outcome as compared to treatment with rtPA plus empty LCL or free DXP. Acute and final brain lesion sizes were comparable between treatment groups; however a predictive algorithm revealed a significantly larger salvaged tissue area after treatment with LCL-DXP. We conclude that delivery of dexamethasone phosphate via LCL in combination with rtPA-induced thrombolysis can significantly improve outcome after stroke. Furthermore, magnetic resonance imaging-based predictive algorithms provide a sensitive means to measure treatment effects on lesion development., The research leading to these results was funded by the Netherlands Heart Foundation (2005B156), The Netherlands Organization for Scientific Research (NWO-Vidi 917.76.351), and the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreements nº 201024 and nº 202213 (European Stroke Network) and MediTrans., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats

  • Campos-Martorell, Mireia
  • Cano-Sarabia, Mary
  • Simats, Alba
  • Hernández-Guillamón, Mar
  • Rosell, Anna
  • Maspoch, Daniel
  • Montaner, Joan
[Background and aims]: Although the beneficial effects of statins on stroke have been widely demonstrated both in experimental studies and in clinical trials, the aim of this study is to prepare and characterize a new liposomal delivery system that encapsulates simvastatin to improve its delivery into the brain. [Materials and methods]: In order to select the optimal liposome lipid composition with the highest capacity to reach the brain, male Wistar rats were submitted to sham or transitory middle cerebral arterial occlusion (MCAOt) surgery and treated (intravenous [IV]) with fluorescent-labeled liposomes with different net surface charges. Ninety minutes after the administration of liposomes, the brain, blood, liver, lungs, spleen, and kidneys were evaluated ex vivo using the Xenogen IVIS® Spectrum imaging system to detect the load of fluorescent liposomes. In a second substudy, simvastatin was assessed upon reaching the brain, comparing free and encapsulated simvastatin (IV) administration. For this purpose, simvastatin levels in brain homogenates from sham or MCAOt rats at 2 hours or 4 hours after receiving the treatment were detected through ultra-high-protein liquid chromatography. [Results]: Whereas positively charged liposomes were not detected in brain or plasma 90 minutes after their administration, neutral and negatively charged liposomes were able to reach the brain and accumulate specifically in the infarcted area. Moreover, neutral liposomes exhibited higher bioavailability in plasma 4 hours after being administered. The detection of simvastatin by ultra-high-protein liquid chromatography confirmed its ability to cross the blood-brain barrier, when administered either as a free drug or encapsulated into liposomes. [Conclusion]: This study confirms that liposome charge is critical to promote its accumulation in the brain infarct after MCAOt. Furthermore, simvastatin can be delivered after being encapsulated. Thus, simvastatin encapsulation might be a promising strategy to ensure that the drug reaches the brain, while increasing its bioavailability and reducing possible side effects., The research leading to these results received funding from the European Union’s Seventh Framework Program (FP7/2007-2013) under grant agreements number 201024 and number 202213 (European Stroke Network). Neurovascular Research Laboratory takes part in the Spanish stroke research network INVICTUS (RD12/0014/0005). This study was partially funded by projects FIS 11/0176 on stroke biomarkers research and EC07/90195 on increasing safety and efficacy of simvastatin neuroprotection., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after Stroke

  • Ulm, Lena
  • Hoffmann, Sarah
  • Nabavi, Darius
  • Hermans, Marcella
  • Mackert, Bruno-Marcel
  • Hamilton, Frank
  • Montaner Villalonga, Joan
  • Bustamante Rangel, Alejandro
Profilaxi antibiòtica; Infeccions; Pneumònia, Profilaxis antibiótica; Infecciones; Neumonía, Antibiotic prophylaxis; Infections; Pneumonia, Background: Pneumonia is among the most common acute complications after stroke and is associated with poor long-term outcome. Biomarkers may help identifying stroke patients at high risk for developing stroke-associated pneumonia (SAP) and to guide early treatment. Aims: This trial investigated whether procalcitonin (PCT) ultrasensitive (PCTus)-guided antibiotic treatment of SAP can improve functional outcome after stroke. Methods: In this international, multicenter, randomized, controlled clinical trial with blinded assessment of outcomes, patients with severe ischemic stroke in the middle cerebral artery territory were randomly assigned within 40 h after symptom onset to PCTus-based antibiotic therapy guidance in addition to stroke unit care or standard stroke unit care alone. The primary endpoint was functional outcome at 3 months, defined according to the modified Rankin Scale (mRS) and dichotomized as acceptable (≤4) or unacceptable (≥5). Secondary endpoints included usage of antibiotics, infection rates, days of fever, and mortality. The trial was registered with http://ClinicalTrials.gov (Identifier NCT01264549). Results: In the intention-to-treat-analysis based on 227 patients (112 in PCT and 115 in control group), 197 patients completed the 3-month follow-up. Adherence to PCT guidance was 65%. PCT-guided therapy did not improve functional outcome as measured by mRS (odds ratio 0.79; 95% confidence interval 0.45–1.35, p = 0.47). Pneumonia rate and mortality were similar in both groups. Days with fever tended to be lower (p = 0.055), whereas total number of days treated with antibiotics were higher (p = 0.004) in PCT compared to control group. A post hoc analysis including all PCT values in the intention-to-treat population demonstrated a significant increase on the first day of infection in patients with pneumonia and sepsis compared to patients with urinary tract infections or without infections (p < 0.0001). Conclusion: PCTus-guided antibiotic therapy did not improve functional outcome at 3 months after severe ischemic stroke. PCT is a promising biomarker for early detection of pneumonia and sepsis in acute stroke patients., This trial was supported by the European Union (FP7/2008-2013; 201024 and 202213), the German Ministry for Health and Education (01EO0801), the German Research Foundation (Exc257, SFB-TRR84, UL423/1-1), and Thermo Fisher Scientific BRAHMS GmbH, Germany.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

DNA methylation levels are highly correlated between pooled samples and averaged values when analysed using the Infinium HumanMethylation450 BeadChip array

  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Carrera, Caty|||0000-0002-0804-0969
  • Muiño, Elena|||0000-0001-5839-7328
  • Montaner, Joan|||0000-0003-4845-2279
  • Krupinski, Jurek
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
DNA methylation is a heritable and stable epigenetic mark implicated in complex human traits. Epigenome-wide association studies (EWAS) using array-based technology are becoming widely used to identify differentially methylated sites associated with complex diseases. EWAS studies require large sample sizes to detect small effects, which increases project costs. In the present study we propose to pool DNA samples in methylation array studies as an affordable and accurate alternative to individual samples studies, in order to reduce economic costs or when low amounts of DNA are available. For this study, 20 individual DNA samples and 4 pooled DNA samples were analysed using the Illumina Infinium HumanMethylation450 BeadChip array to evaluate the efficiency of the pooling approach in EWAS studies. Statistical power calculations were also performed to discover the minimum sample size needed for the pooling strategy in EWAS. A total of 485,577 CpG sites across the whole genome were assessed. Comparison of methylation levels of all CpG sites between individual samples and their related pooled samples revealed highly significant correlations (rho.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats

  • Campos Martorell, Mireia
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Simats Oriol, Alba|||0000-0002-0415-1135
  • Hernández Guillamón, Maria Mar
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Montaner, Joan|||0000-0003-4845-2279
Although the beneficial effects of statins on stroke have been widely demonstrated both in experimental studies and in clinical trials, the aim of this study is to prepare and characterize a new liposomal delivery system that encapsulates simvastatin to improve its delivery into the brain. In order to select the optimal liposome lipid composition with the highest capacity to reach the brain, male Wistar rats were submitted to sham or transitory middle cerebral arterial occlusion (MCAOt) surgery and treated (intravenous [IV]) with fluorescent-labeled liposomes with different net surface charges. Ninety minutes after the administration of liposomes, the brain, blood, liver, lungs, spleen, and kidneys were evaluated ex vivo using the Xenogen IVIS ® Spectrum imaging system to detect the load of fluorescent liposomes. In a second substudy, simvastatin was assessed upon reaching the brain, comparing free and encapsulated simvastatin (IV) administration. For this purpose, simvastatin levels in brain homogenates from sham or MCAOt rats at 2 hours or 4 hours after receiving the treatment were detected through ultra-high-protein liquid chromatography. Whereas positively charged liposomes were not detected in brain or plasma 90 minutes after their administration, neutral and negatively charged liposomes were able to reach the brain and accumulate specifically in the infarcted area. Moreover, neutral liposomes exhibited higher bioavailability in plasma 4 hours after being administered. The detection of simvastatin by ultra-high-protein liquid chromatography confirmed its ability to cross the blood-brain barrier, when administered either as a free drug or encapsulated into liposomes. This study confirms that liposome charge is critical to promote its accumulation in the brain infarct after MCAOt. Furthermore, simvastatin can be delivered after being encapsulated. Thus, simvastatin encapsulation might be a promising strategy to ensure that the drug reaches the brain, while increasing its bioavailability and reducing possible side effects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Randomized Controlled STRAWINSKI Trial, Procalcitonin-Guided Antibiotic Therapy after Stroke

  • Ulm, Lena|||0000-0002-3388-8785
  • Hoffmann, Sarah
  • Nabavi, Darius
  • Hermans, Marcella
  • Mackert, Bruno-Marcel
  • Hamilton, Frank
  • Schmehl, Ingo
  • Jungehuelsing, Gerhard-Jan
  • Montaner, Joan|||0000-0003-4845-2279
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Katan, Mira
  • Hartmann, Andreas
  • Ebmeyer, Stefan
  • Dinter, Christiane
  • Wiemer, Jan C.
  • Hertel, Sabine
  • Meisel, Christian
  • Anker, Stefan|||0000-0002-0805-8683
  • Meisel, Andreas
Pneumonia is among the most common acute complications after stroke and is associated with poor long-term outcome. Biomarkers may help identifying stroke patients at high risk for developing stroke-associated pneumonia (SAP) and to guide early treatment. This trial investigated whether procalcitonin (PCT) ultrasensitive (PCTus)-guided antibiotic treatment of SAP can improve functional outcome after stroke. In this international, multicenter, randomized, controlled clinical trial with blinded assessment of outcomes, patients with severe ischemic stroke in the middle cerebral artery territory were randomly assigned within 40 h after symptom onset to PCTus-based antibiotic therapy guidance in addition to stroke unit care or standard stroke unit care alone. The primary endpoint was functional outcome at 3 months, defined according to the modified Rankin Scale (mRS) and dichotomized as acceptable (≤4) or unacceptable (≥5). Secondary endpoints included usage of antibiotics, infection rates, days of fever, and mortality. The trial was registered with (Identifier NCT01264549). In the intention-to-treat-analysis based on 227 patients (112 in PCT and 115 in control group), 197 patients completed the 3-month follow-up. Adherence to PCT guidance was 65%. PCT-guided therapy did not improve functional outcome as measured by mRS (odds ratio 0.79; 95% confidence interval 0.45-1.35, p = 0.47). Pneumonia rate and mortality were similar in both groups. Days with fever tended to be lower (p = 0.055), whereas total number of days treated with antibiotics were higher (p = 0.004) in PCT compared to control group. A post hoc analysis including all PCT values in the intention-to-treat population demonstrated a significant increase on the first day of infection in patients with pneumonia and sepsis compared to patients with urinary tract infections or without infections (p < 0.0001). PCTus-guided antibiotic therapy did not improve functional outcome at 3 months after severe ischemic stroke. PCT is a promising biomarker for early detection of pneumonia and sepsis in acute stroke patients.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after Stroke

  • Ulm, Lena
  • Hoffmann, Sarah
  • Nabavi, Darius
  • Hermans, Marcella
  • Mackert, Bruno-Marcel
  • Hamilton, Frank
  • Montaner Villalonga, Joan
  • Bustamante Rangel, Alejandro
Profilaxi antibiòtica; Infeccions; Pneumònia, Profilaxis antibiótica; Infecciones; Neumonía, Antibiotic prophylaxis; Infections; Pneumonia, Background: Pneumonia is among the most common acute complications after stroke and is associated with poor long-term outcome. Biomarkers may help identifying stroke patients at high risk for developing stroke-associated pneumonia (SAP) and to guide early treatment. Aims: This trial investigated whether procalcitonin (PCT) ultrasensitive (PCTus)-guided antibiotic treatment of SAP can improve functional outcome after stroke. Methods: In this international, multicenter, randomized, controlled clinical trial with blinded assessment of outcomes, patients with severe ischemic stroke in the middle cerebral artery territory were randomly assigned within 40 h after symptom onset to PCTus-based antibiotic therapy guidance in addition to stroke unit care or standard stroke unit care alone. The primary endpoint was functional outcome at 3 months, defined according to the modified Rankin Scale (mRS) and dichotomized as acceptable (≤4) or unacceptable (≥5). Secondary endpoints included usage of antibiotics, infection rates, days of fever, and mortality. The trial was registered with http://ClinicalTrials.gov (Identifier NCT01264549). Results: In the intention-to-treat-analysis based on 227 patients (112 in PCT and 115 in control group), 197 patients completed the 3-month follow-up. Adherence to PCT guidance was 65%. PCT-guided therapy did not improve functional outcome as measured by mRS (odds ratio 0.79; 95% confidence interval 0.45–1.35, p = 0.47). Pneumonia rate and mortality were similar in both groups. Days with fever tended to be lower (p = 0.055), whereas total number of days treated with antibiotics were higher (p = 0.004) in PCT compared to control group. A post hoc analysis including all PCT values in the intention-to-treat population demonstrated a significant increase on the first day of infection in patients with pneumonia and sepsis compared to patients with urinary tract infections or without infections (p < 0.0001). Conclusion: PCTus-guided antibiotic therapy did not improve functional outcome at 3 months after severe ischemic stroke. PCT is a promising biomarker for early detection of pneumonia and sepsis in acute stroke patients., This trial was supported by the European Union (FP7/2008-2013; 201024 and 202213), the German Ministry for Health and Education (01EO0801), the German Research Foundation (Exc257, SFB-TRR84, UL423/1-1), and Thermo Fisher Scientific BRAHMS GmbH, Germany.